This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ESMO-Asia, Singapore 22-24 November 2019

Activity of afatinib in patients with EGFR mutation-positive NSCLC and baseline brain metastases: pooled analysis of three large Phase IIIb trials​


Maya Gottfried, Filippo de Marinis, Haiyan Tu, Konstantin K. Laktionov, Jifeng Feng, Artem Poltoratskiy, Jun Zhao, Eng-Huat Tan, Victor Lee, Dariusz Kowalski, Cheng-Ta Yang, BJ Srinivasa, Antonio Passaro, Laura Clementi, Wenbo Tang, Dennis Chin-Lun Huang, Agnieszka Cseh, Keunchil Park, Caicun Zhou, Yi-Long Wu


Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC

J Thorac Oncol. 2016 Mar;11(3):380-90.